Merck

Effect of emulin on blood glucose in type 2 diabetics.

Journal of medicinal food (2013-03-01)
Milton Joseph Ahrens, Daryl L Thompson
ABSTRACT

Emulin™ is a patented blend of chlorogenic acid, myricetin, and quercetin that has shown efficacy in reducing midday and post-oral glucose tolerance test (OGTT) area under the curve (AUC) glucose in streptozotocin-treated rats. The purpose of this study was to determine if similar effects would be evident in type 2 diabetic humans. Forty human subjects with confirmed type 2 diabetes (10 each in 4 groups: placebo/no medication, Emulin/no medication, placebo/metformin and Emulin/metformin) were evaluated. At the end of 1 week, fasting blood glucose, 2 h postprandial, actual peak glucose, and AUC (post-50 g OGTT) were determined. The placebo-only group had a large (5%-13%) increase in all parameters. The Emulin group and those on metformin performed similarly with reductions between 1% and 5%, with Emulin slightly outperforming the medication-alone group. The most significant reduction occurred in the Emulin/metformin group, with decreases in the parameters by up to 20%. These results suggest that Emulin, if consumed regularly, could not only have the acute effect of lowering the glycemic impact of foods, but chronically lower background blood glucose levels of type 2 diabetics.

MATERIALS
Product Number
Brand
Product Description

Sigma-Aldrich
Myricetin, ≥96.0% (HPLC)
Sigma-Aldrich
Myricetin, ≥96.0%, crystalline
Supelco
Myricetin, analytical standard
Sigma-Aldrich
Chlorogenic acid, ≥95% (titration)
Chlorogenic acid, primary reference standard